Scholarlink

Background <p>Real-world evidence on quality of life (QoL) changes associated with treatment decisions is crucial for informed choices by patients with low-risk prostate cancer (LRPC).</p> Methods <p>A prospective cohort study was conducted in the Piemonte and Valle d’Aosta Regional Oncology Network, NW Italy (4.5 million population), including nearly all urology (<i>N</i> = 22) and radiation oncology (<i>N</i> = 6) centres. Patients newly diagnosed with LRPC, eligible for radical treatments, received balanced information on risks and benefits of available options and could choose among active surveillance (AS), radical prostatectomy (RP), or radiotherapy (RT). Longitudinal changes in QoL were assessed via patient-reported outcomes in four domains: general QoL, mental health, sexual function and urinary/bowel symptoms. The main comparison was between AS and RP. A secondary comparison was between AS and all radical treatments (RP or RT). Data were analysed by multivariable generalised linear or logistic models, following the intention-to-treat principle and accounting for correlation within centres and subjects.</p> Results <p>A total of 651 patients (76.4% of those enrolled, 559 in AS, 76 in RP and 16 in RT) with baseline questionnaires were included (median [IQR] age, 70 [64–74] years). During a median follow-up of 37 months, no differences in general QoL or mental health were observed between AS and RP. Men in AS had better scores for sexual function (<i>β</i> = 8.27, 95% CI: 5.57–10.96) and activity (<i>β</i> = 6.70, 95% CI: 4.19–9.20). Use of incontinence aids was significantly lower in the AS group (OR = 0.14; 95% CI: 0.09–0.23). Prostatic obstructive symptoms remained stable in AS but decreased in the RP group (OR = 2.77; 95% CI: 1.52–5.06). Results were similar comparing AS to RP or RT.</p> Conclusions <p>Compared to radical prostatectomy, AS preserved urinary continence and sexual function but was associated with persistent obstructive symptoms, without differences in general QoL or mental health. This real-world study supports existing evidence, aiding LRPC patients in making informed decisions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月16日

查看全文
  • Rosalba Rosato,
  • Stefano De Luca,
  • Andrea Zitella,
  • Fernando Munoz,
  • Carlo Giuliano Baima,
  • Maurizio Barale,
  • Franco Bardari,
  • Debora Beldì,
  • Luca Bellei,
  • Andrea Rocco Bellissimo,
  • Diego Bernardi,
  • Giorgio Biamino,
  • Michele Billia,
  • Roberto Borsa,
  • Domenico Cante,
  • Emanuele Castelli,
  • Danilo Centrella,
  • Enrico Checcucci,
  • Devis Collura,
  • Pietro Coppola,
  • Ettore Dalmasso,
  • Andrea Di Stasio,
  • Michele Fiorio,
  • Marco Gatti,
  • Elisabetta Garibaldi,
  • Giuseppe Girelli,
  • Daniele Griffa,
  • Alessia Guarneri,
  • Stefano Guercio,
  • Carlo Giuseppe Iorio,
  • Roberto Migliari,
  • Franco Montefiore,
  • Maurizio Moroni,
  • Giovanni Muto,
  • Marco Oderda,
  • Eva Pagano,
  • Massimo Pasquale,
  • Francesca Ponti di Sant’Angelo,
  • Riccardo Rossi,
  • Luca Ruggiero,
  • Omid Sedigh,
  • Armando Serao,
  • Maria Sara Squeo,
  • Salvatore Stancati,
  • Francesco Varvello,
  • Alessandro Volpe,
  • Stefano Zaramella,
  • Giovanni Zarrelli,
  • Enrico Bollito,
  • Paolo Gontero,
  • Francesco Porpiglia,
  • Claudia Galassi,
  • Giovannino Ciccone,
  • Stefano De Luca,
  • Andrea Di Stasio

摘要

Background

Real-world evidence on quality of life (QoL) changes associated with treatment decisions is crucial for informed choices by patients with low-risk prostate cancer (LRPC).

Methods

A prospective cohort study was conducted in the Piemonte and Valle d’Aosta Regional Oncology Network, NW Italy (4.5 million population), including nearly all urology (N = 22) and radiation oncology (N = 6) centres. Patients newly diagnosed with LRPC, eligible for radical treatments, received balanced information on risks and benefits of available options and could choose among active surveillance (AS), radical prostatectomy (RP), or radiotherapy (RT). Longitudinal changes in QoL were assessed via patient-reported outcomes in four domains: general QoL, mental health, sexual function and urinary/bowel symptoms. The main comparison was between AS and RP. A secondary comparison was between AS and all radical treatments (RP or RT). Data were analysed by multivariable generalised linear or logistic models, following the intention-to-treat principle and accounting for correlation within centres and subjects.

Results

A total of 651 patients (76.4% of those enrolled, 559 in AS, 76 in RP and 16 in RT) with baseline questionnaires were included (median [IQR] age, 70 [64–74] years). During a median follow-up of 37 months, no differences in general QoL or mental health were observed between AS and RP. Men in AS had better scores for sexual function (β = 8.27, 95% CI: 5.57–10.96) and activity (β = 6.70, 95% CI: 4.19–9.20). Use of incontinence aids was significantly lower in the AS group (OR = 0.14; 95% CI: 0.09–0.23). Prostatic obstructive symptoms remained stable in AS but decreased in the RP group (OR = 2.77; 95% CI: 1.52–5.06). Results were similar comparing AS to RP or RT.

Conclusions

Compared to radical prostatectomy, AS preserved urinary continence and sexual function but was associated with persistent obstructive symptoms, without differences in general QoL or mental health. This real-world study supports existing evidence, aiding LRPC patients in making informed decisions.